Vol 24, No 2 (2020)
Original paper
Published online: 2020-06-01

open access

Page views 815
Article views/downloads 713
Get Citation

Connect on Social Media

Connect on Social Media

Neutrophil-to-lymphocyte ratio and pulse wave velocity in patients with controlled systemic hypertension — a preliminary report

Andreea Varga12, Teodor Zah3, Claudia Floriana Suciu1, Dorina Nastasia Petra45, Corneliu Florin Buicu6
Arterial Hypertension 2020;24(2):67-73.

Abstract

Background. Increased arterial stiffness assessed by pulse wave velocity (PWV) measurement is a marker of arterial
wall dysfunction and has an independent predictive value for adverse cardiovascular outcomes. A positive correlation between the neutrophil-to-lymphocyte ratio (NLR) and PWV has been reported in chronic inflammatory conditions and the general population as well.

Furthermore, an association between NLR and PWV has been assumed in hypertensive patients. However, the available data are scarce.

The objective of the study was to validate the association between NLR and PWV in a homogenous group of controlled-hypertensive patients without chronic inflammatory conditions.

Material and methods. A retrospective observational study was conducted in outpatient cardiology and a general practice. A total number of 25 already on-target treated essential hypertensive, non-diabetic and non-chronic kidney disease (non-CKD) patients were selected. PWV was automatically calculated for each patient using the ABPM BPLab® device. The following laboratory data were collected: complete blood count, fibrinogen, alkaline phosphatase, lactate dehydrogenase, uric acid, serum glucose, total cholesterol, triglycerides, iron, calcium, and creatinine.

Neutrophil-to-lymphocyte ratio was calculated. Antihypertensive treatment classes were also assessed.

Results. A correlation between increased NLR and PWV in a homogenous group of controlled-hypertensive patients
was identified.

Conclusions. There is an evident relation between increased NLR and increased PWV in controlled hypertensive
patients without evidence of chronic inflammatory conditions.

Article available in PDF format

View PDF Download PDF file

References

  1. Benjamin E, Virani S, Callaway C, et al. Heart Disease and Stroke Statistics — 2018 Update: A Report From the American Heart Association. Circulation. 2018; 137(12).
  2. Lee HY, Oh BH. Aging and Arterial Stiffness. Circ J. 2010; 74(11): 2257–2262.
  3. Virmani R, Kolodgie F, Burke A, et al. Lessons From Sudden Coronary Death. A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. Arterioscler Thromb Vasc Biol. 2000; 20(5): 1262–1275.
  4. Cavalcante J, Lima J, Redheuil A, et al. Aortic Stiffness. J Am Coll Cardiol. 2011; 57(14): 1511–1522.
  5. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness. J Am Coll Cardiol. 2010; 55(13): 1318–1327.
  6. Omboni S, Posokhov I, Parati G, et al. Ambulatory blood pressure and arterial stiffness web‐based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry. J Clin Hypertens (Greenwich). 2019; 21(8): 1155–1168.
  7. Stehouwer C, Henry R, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008; 51(4): 527–539.
  8. Kinlay S, Creager M, Fukumoto M, et al. Endothelium-Derived Nitric Oxide Regulates Arterial Elasticity in Human Arteries In Vivo. Hypertension. 2001; 38(5): 1049–1053.
  9. Kim HL, Kim SH. Pulse Wave Velocity in Atherosclerosis. Front Cardiovasc Med. 2019; 6: 41.
  10. Ghosh A, Dharmarajan A, Swain P, et al. Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders. Curr Aging Sci. 2019; 11(4): 261–268.
  11. Avolio A, Butlin M, Liu YY, et al. Regulation of arterial stiffness: Cellular, molecular and neurogenic mechanisms. Artery Res 2011; 5(4):122–127. DOI: 10 1016/j artres. 2011; 10: 002.
  12. Townsend R. Arterial stiffness and chronic kidney disease. Curr Opin Nephrol Hypertens. 2015; 24(1): 47–53.
  13. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018; 36(10): 1953–2041.
  14. Laurent S, Cockcroft J, Bortel LV, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21): 2588–2605.
  15. Napoli C, Nigris Fde, Williams-Ignarro S, et al. Nitric oxide and atherosclerosis: An update. Nitric Oxide. 2006; 15(4): 265–279.
  16. Wang M, Jiang L, Monticone R, et al. Proinflammation: the key to arterial aging. Trends Endocrinol Metab . 2014; 25(2): 72–79.
  17. Thijssen D, Carter S, Green D. Arterial structure and function in vascular ageing: are you as old as your arteries? J Physiol. 2015; 594(8): 2275–2284.
  18. Bortel LV, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens . 2012; 30(3): 445–448.
  19. Luzardo L, Lujambio I, Sottolano M, et al. 24-h ambulatory recording of aortic pulse wave velocity and central systolic augmentation: a feasibility study. Hypertens Res. 2012; 35(10): 980–987.
  20. Horváth I, Németh Á, Lenkey Z, et al. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens. 2010; 28(10): 2068–2075.
  21. Omboni S, Posokhov I, Rogoza A. Evaluation of 24-Hour Arterial Stiffness Indices and Central Hemodynamics in Healthy Normotensive Subjects versus Treated or Untreated Hypertensive Patients: A Feasibility Study. Int J Hypertens. 2015; 2015: 1–10.
  22. Mehmet GK. [Inflammation and coronary artery disease: as a new biomarker neutrophil/lymphocyte ratio]. Turk Kardiyol Dern Ars. 2013; 41(3): 191–192.
  23. Balta S, Celik T, Mikhailidis D, et al. The Relation Between Atherosclerosis and the Neutrophil–Lymphocyte Ratio. Clin Appl Thromb Hemost. 2015; 22(5): 405–411.
  24. Karaman M, Balta S, AY S, et al. The Comparative Effects of Valsartan and Amlodipine on vWf Levels and N/L Ratio in Patients with Newly Diagnosed Hypertension. Clin Exp Hypertens. 2013; 35(7): 516–522.
  25. Sharma K, Patel A, Shah K, et al. Is Neutrophil-to-Lymphocyte Ratio a Predictor of Coronary Artery Disease in Western Indians? Int J Inflam. 2017; 2017: 1–8.
  26. Li Y, Chen X, Huang L, et al. Association between neutrophil–lymphocyte ratio and arterial stiffness in patients with acute coronary syndrome. Biosci Rep. 2019; 39(5).
  27. Forget P, Khalifa C, Defour JP, et al. What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes. 2017; 10(1): 12.
  28. Park BJ, Shim JY, Lee HR, et al. Relationship of neutrophil–lymphocyte ratio with arterial stiffness and coronary calcium score. Clin Chim Acta. 2011; 412(11-12): 925–929.
  29. Yang XF, Ding FM, Ye YC, et al. Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus. Chin Med J (Engl). 2018; 131(1): 10–15.
  30. Zanoli L, Ozturk K, Cappello M, et al. Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease. J Am Heart Assoc. 2019; 8(3): e010942.
  31. Wang H, Hu Y, Geng Y, et al. The relationship between neutrophil to lymphocyte ratio and artery stiffness in subtypes of hypertension. J Clin Hypertens (Greenwich). 2017; 19(8): 780–785.
  32. Omboni S, Posokhov I, Kotovskaya Y, et al. Twenty-Four-Hour Ambulatory Pulse Wave Analysis in Hypertension Management: Current Evidence and Perspectives. Curr Hypertens Rep. 2016; 18(10).
  33. Sun X, Luo L, Zhao X, et al. The neutrophil-to-lymphocyte ratio on admission is a good predictor for all-cause mortality in hypertensive patients over 80 years of age. BMC Cardiovascular Disord. 2017; 17(1).
  34. Liu X, Zhang Q, Wu H, et al. Blood Neutrophil to Lymphocyte Ratio as a Predictor of Hypertension. Am J Hypertens. 2015; 28(11): 1339–1346.
  35. Jhuang YH, Kao TW, Peng TC, et al. Neutrophil to lymphocyte ratio as predictor for incident hypertension: a 9-year cohort study in Taiwan. Hypertens Res. 2019; 42(8): 1209–1214.
  36. Balta S, Ozturk C, Yildirim A, et al. The Relation Between Neutrophil–Lymphocyte Ratio and Hypertension. Am J Hypertens. 2015; 28(11): 1386–1386.
  37. Abo T, Kawamura T. Immunomodulation by the Autonomic Nervous System: Therapeutic Approach for Cancer, Collagen Diseases, and Inflammatory Bowel Diseases. Ther Apher. 2002; 6(5): 348–357.
  38. Manolis AJ, Poulimenos LE, Kallistratos MS, et al. Sympathetic overactivity in hypertension and cardiovascular disease. . Curr Vasc Pharmacol. 2014; 12(1): 4–15.
  39. Świerblewska E, Hering D, Kara T, et al. An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans. J Hypertens. 2010; 28(5): 979–984.
  40. Yang XF, Ding FM, Ye YC, et al. Relationship between Neutrophil-to-Lymphocyte Ratio and Pulse Wave Velocity in Young Patients with Systemic Lupus Erythematosus. Chin Med J (Engl). 2018; 131(1): 10–15.
  41. Wang H, Hu Y, Geng Y, et al. The relationship between neutrophil to lymphocyte ratio and artery stiffness in subtypes of hypertension. J Clin Hypertens (Greenwich). 2017; 19(8): 780–785.
  42. Flier J, Underhill L, Brownlee M, et al. Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications. N Engl J Med. 1988; 318(20): 1315–1321.